» Articles » PMID: 21300931

Physical and Psychosocial Recovery in the Year After Primary Treatment of Breast Cancer

Overview
Journal J Clin Oncol
Specialty Oncology
Date 2011 Feb 9
PMID 21300931
Citations 108
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: The 2000 National Institutes of Health Consensus Conference on Adjuvant Therapy of Breast Cancer recommended chemotherapy for all women with invasive cancer greater than 1 centimeter. Studies of long-term breast cancer survivors have found poorer quality of life (QOL) in women who received adjuvant chemotherapy. The aim of this article is to characterize physical and psychosocial recovery as a function of chemotherapy receipt in the year after medical treatment completion.

Patients And Methods: Prospective longitudinal survey data (RAND SF-36 and Breast Cancer Prevention Trial [BCPT] Symptom Scales) collected from 558 women with breast cancer enrolled on the Moving Beyond Cancer (MBC) psychoeducational intervention trial were compared according to receipt of chemotherapy. MBC study enrollment occurred within 4 weeks after the end of primary treatment (eg, surgery, chemotherapy, radiation). Self-report questionnaire data collected at enrollment and at 2, 6, and 12 months thereafter were examined, controlling for intervention and with propensity score adjustment for imbalance of covariates. Outcome analyses were carried out by fitting linear mixed models by using SAS PROC MIXED.

Results: Longitudinal SF-36 scale scores did not differ by chemotherapy treatment exposure, and both groups improved significantly (P < .01) in the year after primary treatment ended. However, adjuvant chemotherapy treatment was associated with significantly more severe physical symptoms, including musculoskeletal pain (P = .01), vaginal problems (P < .01), weight problems (P = .01), and nausea (P = .03).

Conclusion: Physical and psychosocial functioning improved significantly after breast cancer treatment, independent of receipt of adjuvant chemotherapy. Women who received chemotherapy experienced more severe and persistent physical symptoms that should be more effectively managed as part of survivorship care.

Citing Articles

Physical Health Decline After Chemotherapy or Endocrine Therapy in Breast Cancer Survivors.

Bodelon C, Masters M, Bloodworth D, Briggs P, Rees-Punia E, McCullough L JAMA Netw Open. 2025; 8(2):e2462365.

PMID: 40019757 PMC: 11871543. DOI: 10.1001/jamanetworkopen.2024.62365.


Are breast cancer patients with low distress at diagnosis at risk of psychological symptoms later in their disease trajectory? Considerations for when to screen for distress.

Langballe R, Mertz B, Kroman N, Maltesen T, Rosthoj S, Bidstrup P Acta Oncol. 2025; 64:105-113.

PMID: 39863933 PMC: 11788679. DOI: 10.2340/1651-226X.2025.42367.


Endocrine treatment mechanisms in triple-positive breast cancer: from targeted therapies to advances in precision medicine.

Yang X, Yang D, Qi X, Luo X, Zhang G Front Oncol. 2025; 14():1467033.

PMID: 39845328 PMC: 11753220. DOI: 10.3389/fonc.2024.1467033.


Prevalence and associated factors of psychological distress among patients with breast cancer: a systematic review and meta-analysis.

Tang W, Mangantig E, Iskandar Y, Cheng S, Yusuf A, Jia K BMJ Open. 2024; 14(9):e077067.

PMID: 39327054 PMC: 11429273. DOI: 10.1136/bmjopen-2023-077067.


Health-Related Quality of Life and Associated Comorbidities in Community-Dwelling Women with Breast Cancer.

Jang D, Nam H, Kim J, Kim Y J Clin Med. 2024; 13(17).

PMID: 39274534 PMC: 11396280. DOI: 10.3390/jcm13175321.


References
1.
Ganz P, Rowland J, Desmond K, Meyerowitz B, Wyatt G . Life after breast cancer: understanding women's health-related quality of life and sexual functioning. J Clin Oncol. 1998; 16(2):501-14. DOI: 10.1200/JCO.1998.16.2.501. View

2.
Costanzo E, Lutgendorf S, Mattes M, Trehan S, Robinson C, Tewfik F . Adjusting to life after treatment: distress and quality of life following treatment for breast cancer. Br J Cancer. 2007; 97(12):1625-31. PMC: 2360272. DOI: 10.1038/sj.bjc.6604091. View

3.
Hays R, Sherbourne C, Mazel R . The RAND 36-Item Health Survey 1.0. Health Econ. 1993; 2(3):217-27. DOI: 10.1002/hec.4730020305. View

4.
Scheier M, Helgeson V . Really, disease doesn't matter? A commentary on correlates of depressive symptoms in women treated for early-stage breast cancer. J Clin Oncol. 2006; 24(16):2407-8. DOI: 10.1200/JCO.2005.05.5244. View

5.
Ware Jr J, Sherbourne C . The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992; 30(6):473-83. View